Actively Recruiting
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Led by Craig Hospital · Updated on 2025-11-21
48
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
C
Craig Hospital
Lead Sponsor
U
University of Colorado, Boulder
Collaborating Sponsor
AI-Summary
What this Trial Is About
Heart attacks and strokes are among the most common causes of premature death in individuals living with spinal cord injury (SCI) and appear to occur earlier in life. The factors that lead to the heighten and accelerated risk of heart attacks and strokes in adults living with SCI remain poorly understood. The investigators aim to uncover why this happens and find ways to prevent it. Our research focuses on how important cells which line blood vessels, called endothelial cells, function after SCI. The investigators test endothelial function in live conscious people with SCI. The investigators also study signaling molecules endothelial cells release called endothelial cell derived microvesicles (EMVs), which the investigators can measure in blood to tell us the health of endothelial cells. By using these rigorous tests of vascular function, the investigators have determined that endothelial cells appear dysfunctional after SCI. The investigators also know that many men with SCI have low testosterone levels. Our team has studied testosterone's effects on endothelial dysfunction and believe low testosterone may be contributing to endothelial dysfunction after SCI. By understanding these mechanisms, the investigators hope to improve the lives of those living with SCI and reduce their risk for heart attacks and strokes. The investigators propose to study the influence of testosterone on endothelial function by using state-of-the-art clinical and laboratory experiments to assess endothelial function in men with SCI with low and normal testosterone levels.
CONDITIONS
Official Title
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between ages 18-89 years of age
- Male Sex
- History of motor complete (AIS A/B) paraplegia (NLI T3 or Below)
- Time since injury <6 months at time of enrollment (Subacute injury)
- Testosterone Deficiency defined as < 300ng/dL
You will not qualify if you...
- Overt cardiovascular disease assessed by medical history, physical examination, or electrocardiogram
- Anaphylaxis to betadine, lidocaine, or iodine
- Active infection at time of enrollment
- Recent surgery (<1 month) at time of enrollment
- History of smoking tobacco currently or in the past 12 months
- History of more than low-risk alcohol consumption
- History of drug abuse
- Use of cardiovascular-acting therapeutics such as statins or beta-blockers
- Other health habits, medications, or supplements that could influence the study outcomes as determined by the research team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Craig Hospital
Englewood, Colorado, United States, 80113
Actively Recruiting
Research Team
G
Genevieve Madera, BS
CONTACT
A
Andrew Park, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here